These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3594716)

  • 1. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.
    Kim S; Kim DJ; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(4):307-10. PubMed ID: 3594716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy.
    Kim S; Howell SB
    Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
    Rahman YE; Patel KR; Cerny EA; Maccoss M
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
    Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
    Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.
    Parker RJ; Priester ER; Sieber SM
    Drug Metab Dispos; 1982; 10(1):40-6. PubMed ID: 6124381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].
    Fu NW
    Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivesicular liposomes containing cytarabine for slow-release Sc administration.
    Kim S; Howell SB
    Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
    Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
    Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size.
    Hunt CA; Rustum YM; Mayhew E; Papahadjopoulos D
    Drug Metab Dispos; 1979; 7(3):124-8. PubMed ID: 38080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
    Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
    Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
    Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
    Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.
    King ME; Pfeifle CE; Howell SB
    J Clin Oncol; 1984 Jun; 2(6):662-9. PubMed ID: 6726304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
    Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
    Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
    [No Abstract]   [Full Text] [Related]  

  • 17. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat.
    McCullough HN; Juliano RL
    J Natl Cancer Inst; 1979 Sep; 63(3):727-31. PubMed ID: 288932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
    Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
    J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
    Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
    Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
    Sinkule JA; Evans WE
    J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.